Rethinking Heart Disease Risk: Beyond Cholesterol with Dr. Michael Blaha

Beyond Cholesterol: A New Look at Heart Disease Risk

• ❤️ Cardiovascular disease remains the leading cause of death in America, despite widespread use of cholesterol-lowering statins.
• 💡 The discussion emphasizes a shift beyond solely focusing on cholesterol to a more comprehensive understanding of heart disease risk factors.

Emerging Risk Factors and Treatments

• 📈 Obesity and diabetes are identified as the current epidemic drivers of heart disease, with GLP-1 agonists showing promise for weight loss and cardiovascular benefits.
• 🧬 Lipoprotein(a) [Lp(a)] is a genetic risk factor for cardiovascular disease, affecting about one in five people, and new therapies are being developed to lower its levels.
• 💊 While statins are effective, they can slightly raise Lp(a) levels, highlighting the complex interplay of different treatments.

Re-evaluating Established Treatments

• 🚫 Beta-blockers, once standard after a heart attack, may not be necessary long-term for patients with good heart function (normal ejection fraction).
• ⚖️ Balancing blood pressure control with the risk of side effects like orthostatic hypotension is crucial, requiring personalized treatment approaches.
• 🏠 Home blood pressure monitoring is highly recommended to get a more accurate picture than clinic measurements alone, due to factors like white coat hypertension and patient anxiety.

Advanced Risk Assessment and Lifestyle

• 🔬 The Coronary Artery Calcium (CAC) score is a valuable tool for assessing plaque burden and personalizing risk, especially for intermediate-risk patients or those with risk-enhancing factors.
• 🚶‍♀️ While general heart-healthy diets and physical activity are recommended for everyone, high-risk patients benefit from more in-depth, tailored lifestyle interventions.
• 🦠 Inflammation, potentially triggered by infections like COVID-19 or chronic conditions, is increasingly recognized as a significant risk factor for cardiovascular disease.

New Frontiers in Cardiovascular Care

• 💊 Colchicine, an anti-inflammatory drug, is showing promise in reducing cardiovascular risk, particularly for patients with inflammation and high risk.
• 🚀 New drug classes, such as apricetanin (Trivio), a dual endothelin receptor antagonist, offer novel mechanisms for treating resistant hypertension.
• 🩺 The importance of monitoring electrolytes like potassium when using diuretics is stressed, as symptoms can be subtle or absent, necessitating regular lab checks.